OBJECTIVES Study of clinical efficacy, tolerance and economic indicators of treatment of non-severe CAP by (5-day) course of levofloxacin 750 mg/day vs. the standard administration of levofloxacin  500 mg/day METHODS The research included 64 patients having non-severe CAP with risk factors (administration of antibiotics during the preceding 3 months, concomitant diseases), all of them being males. The patients were randomized into 2 groups; the 1^st group received high-dose therapy of levofloxacin, 750 mg/day within 5 days (Remedia, Simpex-Pharma,India).  2^nd group recieved levofloxacin 500 mg/day for 7-10 days (Tavanic^®, Sanofi-Winthrop Ind.). Efficacy and safety were assessed in terms of comprehensive analysis of clinical, laboratory and radiological data. For economic analysis, direct medical costs and “costs-efficacy” ratios (CER) were calculated. RESULTS First group included 32 patients with average age 22.7±1.8 years. Second group  consisted of 32 patients with average  21.8±6 years. Clinical efficacy of high-dose levofloxacin therapy  amounted to 96.9%. Average duration of antibiotic treatment was 5.2±0.9 days..Standard regime by levofloxacin was efficient in 100% of cases. Radiological resolution was identical in both groups .Transient increase of hepatic transaminase activity was present in 3 patients (9.4%). In standard group , this adverse event was present in 4 patients (12.5%). Average treatment cost by levofloxacin 750 mg/day amounted to 13.3±6.2 euros (CER_LEVO-750=13.7); cost of the standard therapy was 27.2±4.9 euros (CER_LEVO-750=27.2). CONCLUSIONS Therefore, in terms of clinical efficacy and safety, the high-dose therapy (750 mg/day) by levofloxacin, in brief course of treatment of patients having non-severe CAP, is comparable with the standard regime of treatment (levofloxacin 500 mg/day for 7 to 10 days);and, is more efficient in economic terms.